Przejdź do
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Wybierz wielkość
Zmień widok
| Gabaryty przesyłki | SKU | Dostępność | Cena netto |
|---|---|---|---|
| 5 mg | Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności | 424,00 zł 360,40 zł | |
| 25 mg | Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności | 1370,00 zł 1164,50 zł |
Informacje o tej pozycji
Wzór empiryczny (zapis Hilla):
C19H23N7O2
Numer CAS:
Masa cząsteczkowa:
381.43
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
360,40 zł
Cena katalogowa424,00 złZaoszczędź 15%Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomócassay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
[nH]1nc(c(c1)NC(=O)NC5CC5)c2[nH]c3c(n2)ccc(c3)CN4CCOCC4
InChI
1S/C19H23N7O2/c27-19(21-13-2-3-13)24-16-10-20-25-17(16)18-22-14-4-1-12(9-15(14)23-18)11-26-5-7-28-8-6-26/h1,4,9-10,13H,2-3,5-8,11H2,(H,20,25)(H,22,23)(H2,21,24,27)
InChI key
LOLPPWBBNUVNQZ-UHFFFAOYSA-N
Biochem/physiol Actions
A multitargeted kinase inhibitor with in vivo anticancer efficacy and potent activity against Abl, aurora kinase A/B and JAK2/3.
AT9283 is an ATP site-targeting pyrazole-benzimidazole-based molecule with inhibitory potency against multiple kinases, most notably Aurora A/B (IC50 ≤3.0 nM), JAK2/3 (IC50 = 1.2/1.1 nM), Abl T315I (IC50 = 4 nM), GSK3β, FGFR2, VEGFR3 (Flt4), Mer, Ret, Rsk2/3, Tyk2, Yes (IC50 = 1-10 nM). AT9283 also inhibits 72 other kinases/mutations at a reduced potency (IC50 = 10-30 nM against 14, 30-100 nM against 21, 100-300 against 37 targets), while displaying an IC50 >300 nM toward 144 other kinase targets. AT9283 inhibits the growth/survival of multiple solid tumor cell lines in vitro (IC50 = 7.7-20 nM) and shows anti-cancer efficacy in mice via i.p. injection in vivo (67% and 76%HCT116 tumor growth inhibition on day 16, respectively, with 15 and 20 mg/kg b.i.d., two-day on and two-day off; >95% inhibition of Ba/F3 ETV6-JAK2 leukemia proliferation on day 12 with 10 mg/kg b.i.d. on days 2–5 and 8–12).
AT9283 has also been shown to accelerate growth arrest in various xenograft models.
Ta strona może zawierać tekst przetłumaczony maszynowo.
1 of 1
Ta pozycja | |||
|---|---|---|---|
| form powder | form powder | form powder | form powder |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay ≥98% (HPLC) |
| storage temp. −20°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| solubility DMSO: 2 mg/mL, clear | solubility DMSO: 2 mg/mL, clear | solubility DMSO: 10 mg/mL, clear | solubility DMSO: 2 mg/mL, clear |
| color white to beige | color white to beige | color white to beige | color white to beige |
Klasa składowania
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Sanne H Olesen et al.
ChemMedChem, 11(11), 1137-1144 (2016-05-03)
Increasing evidence suggests key roles for members of the mammalian Sterile20-like (MST) family of kinases in many aspects of biology. MST3 is a member of the STRIPAK complex, the deregulation of which has recently been associated with cancer cell migration
Mark A Dawson et al.
British journal of haematology, 150(1), 46-57 (2010-05-29)
Constitutive activation of Janus kinase (Jak) 2 is the most prevalent pathogenic event observed in the myeloproliferative disorders (MPD), suggesting that inhibitors of Jak2 may prove valuable in their management. Inhibition of the Aurora kinases has also proven to be
Steven Howard et al.
Journal of medicinal chemistry, 52(2), 379-388 (2009-01-16)
Here, we describe the identification of a clinical candidate via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment. Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive targets for the treatment



